<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[11, 14] pegylated liposomal doxorubicin<br>[15, 17] topotecan.<br>[26, 32] pegylated liposomal doxorubicin (PLD)<br>[33, 34] topotecan<br>[72, 73] PLD<br>[84, 85] topotecan<br>[123, 124] PLD<br>[126, 128] topotecan)<br>[191, 193] topotecan.<br>[206, 207] PLD<br>[222, 223] PLD<br>[227, 229] topotecan.<br>[233, 234] PLD<br>[238, 239] topotecan<br>[268, 269] topotecan<br>[281, 282] topotecan<br>[318, 319] PLD<br></td>
<td width=33%>
[11, 17] pegylated liposomal doxorubicin versus topotecan.<br>[26, 32] pegylated liposomal doxorubicin (PLD)<br>[33, 34] topotecan<br>[52, 57] platinum-based chemotherapy.<br>[72, 74] PLD 50<br>[84, 85] topotecan<br>[123, 124] PLD<br>[126, 128] topotecan)<br>[162, 163] PLD<br>[164, 165] topotecan<br>[186, 187] PLD<br>[191, 193] topotecan.<br>[206, 207] PLD<br>[222, 223] PLD<br>[227, 229] topotecan.<br>[233, 234] PLD<br>[238, 239] topotecan<br>[268, 269] topotecan<br>[281, 282] topotecan<br>[318, 319] PLD<br></td>
<td width=33%>
[11, 18] pegylated liposomal doxorubicin versus topotecan.

<br>[26, 34] pegylated liposomal doxorubicin (PLD) and topotecan<br>[52, 57] platinum-based chemotherapy.<br>[72, 74] PLD 50<br>[84, 85] topotecan<br>[123, 124] PLD<br>[126, 128] topotecan)<br>[132, 136] intent-to-<br>[162, 165] PLD and topotecan<br>[186, 187] PLD<br>[191, 193] topotecan.<br>[206, 208] PLD for<br>[222, 223] PLD<br>[227, 229] topotecan.<br>[233, 234] PLD<br>[238, 239] topotecan<br>[268, 269] topotecan<br>[281, 282] topotecan<br>[318, 319] PLD<br></td>
</tr>
